# Impact of Losartan on Portal Hypertension and Liver Cirrhosis: A Systematic Review

## TL;DR

This study reviews evidence on losartan's effectiveness in reducing portal pressure and liver fibrosis in patients with cirrhosis and portal hypertension.

## Contribution

The study provides a systematic review and meta-analysis of losartan's impact on portal hypertension compared to propranolol.

## Key findings

- Losartan significantly reduced wedged hepatic venous pressure compared to propranolol.
- Losartan affected mean arterial pressure, renal function, and hepatic fibrosis.
- Losartan may offer benefits in treating both hemodynamic and structural aspects of liver cirrhosis.

## Abstract

Portal hypertension, a complication of chronic liver disease, results from an elevated pressure gradient between the portal vein and the inferior vena cava. While non-selective beta-blockers are established for reducing portal pressure, the efficacy of losartan, an angiotensin II receptor blocker, remains debated. This study evaluated losartan's impact on portal pressure and liver fibrosis in patients with cirrhosis and portal hypertension.

The goal of this meta-analysis was to appraise evidence on the role of losartan in reducing portal pressure and associated clinical outcomes in cirrhotic patients with portal hypertension.

A comprehensive literature search was conducted in PubMed, Cochrane Library, Medline, and Web of Science. All the research and literature review were conducted from August 20th, 2024, through August 31st, 2024 (within one month of the paper's submission). The Risk of Bias Visualization Tool (Robvis 2.0) and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) were used to assess study quality. Data were extracted and analyzed using Microsoft Excel.

Among 426 potential studies, 12 met the inclusion criteria. Both losartan and propranolol reduced hepatic venous pressure gradient (HVPG), with some studies suggesting a more pronounced effect of losartan. A meta-analysis found no significant difference in HVPG reduction (p = 0.22), but losartan significantly reduced wedged hepatic venous pressure (WHVP) compared to propranolol (p = 0.03). Losartan also affected mean arterial pressure, renal function, and hepatic fibrosis.

Losartan shows potential in treating portal hypertension by reducing portal pressure and fibrosis. It may be particularly beneficial in the treatment of liver cirrhosis by addressing both hemodynamic and structural components and improving sodium handling in complex cases.